Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 98

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 98
---
, through an execution of the plan or an announcement of its main features to those affected by it, a valid expectation has been raised in those affected by the plan that the plan will be implemented. The recognition of restructuring provision requires estimates including timing of payments and the number of individuals impacted by the restructuring. As a result of these estimates, the actual restructuring costs may differ from our estimates.

On May 9, 2024, we announced a multi-year, enterprise-wide efficiency program aimed at promoting business growth and improving our profitability. This program includes increasing the agility and simplicity of our business organization, investing in digital, data and technology to enhance productivity and efficiency across the organization and implementing cost reductions and process improvements in supply chain and vendor management. Primarily as a result of the initiatives announced in May 2024, we recorded JPY 128.1 billion of restructuring expenses in the fiscal year ended March 31, 2025 and currently expect to incur JPY 48.0 billion of restructuring expenses in the fiscal year ending March 31, 2026, with lower expenses in the fiscal years to follow.

As of March 31, 2025, we had a provision of JPY 14.0 billion for restructuring costs. See Note 23 to our audited consolidated financial statements for a further description of our restructuring provisions and the change between periods.

Table of Contents

Results of Operations

The following table provides selected consolidated statements of profit or loss information for the years ended March 31, 2023, 2024 and 2025.

                                                                                        For the fiscal year ended March 31,                                                                         
                                                                                                                       2023                        2024                        2025                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                                          (billions of yen)                                                                         
  Revenue                                                                                                                 ¥        4,027.5            ¥        4,263.8            ¥        4,581.6  
  Cost of sales                                                                                                                  (1,244.1)                   (1,426.7)                   (1,580.2)  
  Selling, general and administrative expenses                                                                      (997.3)                                  (1,053.8)                   (1,104.8)  
  Research and development expenses                                                                                 (633.3)                     (729.9)                     (730.2)                 
  Amortization and impairment losses on intangible assets associated with products                                  (